journal article·2023-03Open access

Dual-responsive metal organic framework for electrically-enhanced cascade catalytic tumor therapy

Junge Zhao, Liping Liu, Liyuan Gu, Zeyu Li, Yilong Li, Zhiguang Wu, Bei Sun, Xijin Wang, Tiedong Sun

Abstract

Chemodynamic Therapy (CDT) based on Fenton reaction that can produce highly toxic reactive oxygen species to kill cancer cells has attracted considered attention. However, the effect of the CDT is limited in specific conditions (e.g. pH and H2O2 content) in tumor microenvironment (TME). In this paper, a glucose oxidase (GOx) and Fe3+-loaded metal organic framework system ([email protected]@Fe3+), to enhance the cascade reaction of the therapy, was developed for combined starvation therapy and CDT with the assistance of electrolysis. The [email protected]@Fe3+ in the tumor microenvironment was decomposed and thus released the Fe3+ and GOx. The electrolysis procedure, can not only trigger the Fe3+ and Fe2+ cyclic reactions, also provided O2 for the oxidation and decomposition of glucose to generate H2O2. This resulted in the improvement of the pH in TME for Fenton reaction, to enhance the CDT treatment effect. Meanwhile, glucose and O2 were consumed by GOx to achieve the effect of blocking nutrients. Compared with other control groups, the [email protected]@Fe3+ under electrolysis showed the considerable inhibitory effect of tumor cells, and the apoptosis rate even reached 80%. Our work presents an ingenious nanoenzyme for Fenton reactions that achieves a self-supplying strategy under electrolysis to improve anti-tumor efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (33)

Show source-provided references
1. Meng · Appl. Mater. Today · 2020 · 21
2. Ma · Nano Lett. · 2017 · 17 · 92810.1021/acs.nanolett.6b04269 ↗
3. Hu · Biomaterials · 2017 · 141 · 8610.1016/j.biomaterials.2017.06.035 ↗
4. Oh · Kor. J. Chem. Eng. · 2016 · 33 · 88510.1007/s11814-015-0204-x ↗
5. Salgado · Appl. Catal., B · 2018 · 226 · 9310.1016/j.apcatb.2017.12.035 ↗
6. Chudal · ACS Appl. Bio Mater. · 2020 · 3 · 180410.1021/acsabm.0c00098 ↗
7. Liu · Adv. Funct. Mater. · 2019 · 29
8. Chang · ACS Appl. Bio Mater. · 2020 · 10 · 714710.1021/acsabm.0c00949 ↗
9. Wang · Colloids Surf., B · 2020 · 192
10. Chen · Adv. Mater. · 2020 · 32
11. Cheng · New J. Chem. · 2020 · 44 · 152410.1039/C9NJ05469C ↗
12. Ma · Bioact. Mater. · 2021 · 6 · 4558
13. Lin · Front. Oncol. · 2020 · 10
14. Denko · Nat. Rev. Cancer · 2008 · 8 · 70510.1038/nrc2468 ↗
15. Koppenol · Nat. Rev. Cancer · 2011 · 11 · 61810.1038/nrc3108 ↗
16. Krisher · Mol. Reprod. Dev. · 2012 · 79 · 31110.1002/mrd.22037 ↗
17. Yu · J. Cancer · 2018 · 9 · 369910.7150/jca.27279 ↗
18. Yu · Theranostics · 2019 · 9 · 802610.7150/thno.38261 ↗
19. Zhang · ACS Nano · 2018 · 12 · 1020110.1021/acsnano.8b05200 ↗
20. Wang · Angew. Chem. Int. Ed. · 2017 · 56 · 1608210.1002/anie.201710418 ↗
21. Wei · Biomaterials · 2020 · 238
22. Chang · Adv. Mater. · 2019 · 3110.1002/adma.201905271 ↗
23. He · Biomater Sci-Uk · 2019 · 7 · 426010.1039/C9BM00797K ↗
24. Yang · Pharmacol. Res. · 2017 · 126 · 9710.1016/j.phrs.2017.05.004 ↗
25. Wang · J. Exp. Clin. Cancer Res. · 2021 · 40 · 2410.1186/s13046-020-01820-7 ↗
26. Lou · Acc. Chem. Res. · 2015 · 48 · 135810.1021/acs.accounts.5b00009 ↗
27. Shen · Biomaterials · 2020 · 25110.1016/j.biomaterials.2020.120079 ↗
28. Lopez-Lazaro · Cancer Lett. · 2007 · 252 · 110.1016/j.canlet.2006.10.029 ↗
29. Wlassoff · J. Pharm. Pharmacol. · 2007 · 59 · 154910.1211/jpp.59.11.0013 ↗
30. Liu · Biomater. Sci. · 2019 · 7 · 368310.1039/C9BM00641A ↗
31. Wan · ACS Nano · 2020 · 14 · 1101710.1021/acsnano.9b07789 ↗
32. Zhang · Adv. Mater. · 2022 · 34
33. Lu · Adv. Sci. · 2020 · 710.1002/advs.202001223 ↗